The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia.
Muriuki JM., Mentzer AJ., Band G., Gilchrist JJ., Carstensen T., Lule SA., Goheen MM., Joof F., Kimita W., Mogire R., Cutland CL., Diarra A., Rautanen A., Pomilla C., Gurdasani D., Rockett K., Mturi N., Ndungu FM., Scott JAG., Sirima SB., Morovat A., Prentice AM., Madhi SA., Webb EL., Elliott AM., Bejon P., Sandhu MS., Hill AVS., Kwiatkowski DP., Williams TN., Cerami C., Atkinson SH.
Iron acquisition is critical for life. Ferroportin (FPN) exports iron from mature erythrocytes, and deletion of the Fpn gene results in hemolytic anemia and increased fatality in malaria-infected mice. The FPN Q248H mutation (glutamine to histidine at position 248) renders FPN partially resistant to hepcidin-induced degradation and was associated with protection from malaria in human studies of limited size. Using data from cohorts including over 18,000 African children, we show that the Q248H mutation is associated with modest protection against anemia, hemolysis, and iron deficiency, but we found little evidence of protection against severe malaria or bacteremia. We additionally observed no excess Plasmodium growth in Q248H erythrocytes ex vivo, nor evidence of selection driven by malaria exposure, suggesting that the Q248H mutation does not protect from malaria and is unlikely to deprive malaria parasites of iron essential for their growth.